Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Professor M. Asim Beg and the COPCOV team at Aga Khan University in Pakistan © Asim Beg

"As of COB 29 July, COPCOV has now recruited 1637 participants -- making it the largest pre-exposure prophylaxis study in the world! There is still a way to go, as there remains so much potential in this study, but this is a fantastic milestone. Congratulations, everyone!" said COPCOV Co-PI Dr Will Schilling.

Funded by Wellcome and led by MORU, COPCOV is currently recruiting in Indonesia, Kenya, Zambia, Benin, Côte d’Ivoire and Mali. The global study hopes to open in the coming weeks new study sites in Benin, Ethiopia, Indonesia, Kenya, Nepal and Niger.

Recruitment into the COPCOV study at Aga Khan University slowed earlier in the year due to high COVID-19 vaccination coverage among healthcare worker staff. Following a change in recruitment strategy, the team pivoted to a community-based approach. Although this new approach presented many challenges, a tremendous effort from all those involved led, in less than six weeks, to 381 participants being recruited into COPCOV. This brought the total number of participants recruited at the site to 399 and marks a COPCOV milestone as Aga Khan becomes the first site to hit their recruitment target (400 could not be achieved due one study drug kit being damaged).

A huge congratulation to Professor M. Asim Beg (4th from left) and his team (shown celebrating their achievement 20 July) on this truly fantastic effort. 

-  James Callery, on behalf of the COPCOV team, with thanks to Asim Beg for photo.

Similar stories

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.